Edit |   |
---|---|
Antigenic Specificity | Integrin α9β1, Human |
Clone | REA483 |
Host Species | Recombinant Human |
Reactive Species | human, other |
Isotype | IgG1 |
Format | phycoerythrin (PE) conjugate |
Size | 100 tests in 1 mL |
Concentration | 1:11 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Integrin α9β1 Antibody, anti-human, PE, REAfinity™. Clone REA483 recognizes the human integrin α9β1 antigen, a single-pass type I membrane protein which is also known as integrin alpha-RLC. Integrins are heterodimeric glycoprotein receptors and exist as non-covalently bound α and β subunits. The integrin α9β1 binds a number of extracellular matrix components like VCAM1, cytotactin, and osteopontin to mediate cell adhesion, migration, and tissue invasion. Although widely expressed in a variety of normal human cells including endothelium, different types of muscle cells, hepatocytes, and in the hematopoietic system, it is also expressed in cancer cells. Expression of integrin α9β1 in human cancers appears to correlate with higher grade tumors. | Additional information: Clone REA483 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | ITGA9B1, ITGA9, ITGA-RLC, ITGB1 |
Gene, Accession # | Gene ID: 3680, 3688 |
Catalog # | 130-107-128 |
Price | $310 |
Order / More Info | Integrin α9β1, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Kanayama, M. et al. (2011) α9β1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic T?17 cell generation. J Immunol 187 (11): 1271-1281. | Gupta, S. K. et al. (2013) Integrin α9β1 promotes malignant tumor growth and metastasis by potentiating epithelial-mesenchymal transition. Oncogene 32 (2): 141-150. | Ota, D. et al. (2014) Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts. J. Mol. Med. 92 (12): 1271-1281. |